International Society for Hemodialysis™ (ISHD)
Hemodialysis UniversityŽ

August 15 - 16, 2014, Chicago, Illinois USA
     HDCN free zone registration is required.
PART SIX. New Factors in Anemia Management
Overview Of Anemia Management In 2014
Daniel Coyne, MD
Smart Programs For Anemia Management And Practical Tips From The UK
James Tattersall, MD
Questions and Answers
Smart Anemia Management Using Intelligent Systems
Peter Kotanko, MD
Questions and Answers
Anemia And Intensive Dialysis Therapies (Frequent Home Hd Hemodiafiltration, Permeable Membranes)
John Daugirdas, MD
Novel Methods Of Providing Iron: New P Binders And Iron Added
Daniel Coyne, MD

Daniel Coyne, MD
Professor of Medicine (Renal Diseases)
Washington University School of Medicine
St. Louis, Missouri

James Tattersall, MD
Honorary Consultant Nephrologist
Basildon General Hospital
Basildon, UK

Peter Kotanko, MD
Research Director
Renal Research Institute
New York

John T. Daugirdas, MD
Clinical Professor of Medicine
University of Illinois at Chicago School of Medicine
Chicago, Illinois
The live program on which this Web-based educational activity is based was supported by educational grants from Fresenius Medical Care, Dialysis Centers Inc, Baxter Healthcare, and Amgen. No industry funding was provided for support of the Web-based program.

Program Overview
This program will discuss on clinically important problems in dialysis, including home hemodialysis (prescription and delivery), complexities of anemia management, pathogenesis and implications of newly recognized unique complications of hemodialysis, and the value of reporting and analysis of patient reported outcomes in improving quality of hemodialysis.

The program is also aimed at improving the overall level of hemodialysis, and provide a good platform for learning and engage in international exchanges hemodialysis doctors, nurses and engineers.

Educational Objectives
Upon completion of this activity, the participants should be able to:
  • HOME HEMODIALYSIS: Describe methods used to select and train patients for home hemodialysis, manage vascular access, home modification for home hemodialysis, equipment maintenance, remote monitoring, adequacy, and patient safety.
  • ANEMIA: Discuss best practices regarding management of anemia in hemodialysis patients including indications for transfusions, hemoglobin targets, iron use, and anemia management algorithms.
  • Assess how to recognize the “DARK SIDE OF HEMODIALYSIS”, i.e. hemodialysis complications like myocardial and brain stunning, individualized dialysate temperature and cool dialysate.
  • Evaluate ANALYTICAL TECHNIQUES for reporting patient reported outcomes.
Target Audience
This program is designed for health professionals involved in dialysis programs, primarily nephrologists, nephrology fellows, nephrology nurses and nurse practitioners, and patient care technicians.

Physician and Nursing Credit
Although the live programs were prepared under CME accreditation guidelines, no CME/CE credit is available for participating in this Web-archived activity.

Disclosure Policy
Each speaker has completed and signed a conflict of interest statement. The faculty members' relationship will be disclosed in the course materials.

Daniel Coyne, MD, receives grants/research support from Hospira, Celgene, and Deltanoid; consulting fees from Fresenius, Rockwell, and Keryx; and is on the speakers’ bureau for Fresenius Pharma and Abbvie.

James Tattersall, MD, receives consul1ng fees from Johnson & Johnson, and a salary from Medical Health Informatics Limited.

Peter Kotanko, MD, owns stock in Fresenius Medical Care, and receives a salary from Renal Research Institute. Dr. Kotanko holds patents in the field of dialysis.

John T. Daugirdas, MD, is a consultant for Baxter, Fresenius Medical Care, Gambro, B. Braun, and Novaflux. He is a stockholder with ZS Pharma.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. The information presented at this program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, HDCN or the ISHD. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. Before prescribing any medicine, primary references and full prescribing information should be consulted.
This website is managed by HDCN, and their printed privacy policy applies to this site.

The policy statements of HDCN are listed on this page.